T1	Participants 238 298	patients who will benefit from targeted anticancer therapies
T2	Participants 385 479	455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer
T3	Participants 870 916	Eighty-six patients underwent (18)F-FDG PET/CT
